These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1350286)

  • 1. Effect of xamoterol in a patient with idiopathic autonomic failure.
    Elizabeth J; Solomon LR; Lye M
    J Auton Nerv Syst; 1992 Apr; 38(1):65-8. PubMed ID: 1350286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind crossover study of oral xamoterol in postural hypotension due to diabetic autonomic neuropathy.
    Leslie PJ; Thompson C; Clarke BF; Ewing DJ
    Clin Auton Res; 1991 Jun; 1(2):119-23. PubMed ID: 1688039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Xamoterol in the treatment of orthostatic hypotension associated with multiple system atrophy (Shy-Drager syndrome).
    West JN; Stallard TJ; Dimmitt SB; Smith SA; Williams A; Littler WA
    Q J Med; 1990 Feb; 74(274):209-13. PubMed ID: 1971724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Xamoterol in autonomic and intrinsic sinus node dysfunction.
    van den Berg MP; Viersma JW; van Gilst WH; Lie KI
    Am J Cardiol; 1990 Mar; 65(11):814-6. PubMed ID: 1969224
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of xamoterol in acute myocardial infarction: blood pressure, heart rate, arrhythmias and early clinical course.
    McMurray J; Lang CC; MacLean D; Struthers AD; McDevitt DG
    Int J Cardiol; 1991 Jun; 31(3):295-303. PubMed ID: 1679047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Assessment of chronotropic effect and arrhythmogenesis on beta 1-partial agonist (Xamoterol) in chronic heart failure].
    Fukuda K; Handa S; Ogawa S; Nakamura Y; Kawamura Y
    Kokyu To Junkan; 1988 Nov; 36(11):1227-33. PubMed ID: 2907820
    [No Abstract]   [Full Text] [Related]  

  • 7. A comparative study on the ventilatory and haemodynamic effects of xamoterol and atenolol in asthmatic patients.
    Lammers JW; Müller ME; Folgering HT; van Herwaarden CL
    Br J Clin Pharmacol; 1986 Nov; 22(5):595-602. PubMed ID: 2878680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sympathetic modulation in practice: the German clinical experience.
    Kupper W; Erlemeier HH; Bleifeld W
    Eur Heart J; 1990 Apr; 11 Suppl A():19-25. PubMed ID: 1971586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of xamoterol in Shy-Drager syndrome.
    Obara A; Yamashita H; Onodera S; Yahara O; Honda H; Hasebe N
    Circulation; 1992 Feb; 85(2):606-11. PubMed ID: 1346511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of tolerance development after long-term administration of the partial beta-adrenoceptor agonist xamoterol.
    Erlemeier HH; Kupper W; Bleifeld W
    Cardiology; 1990; 77(1):30-9. PubMed ID: 1972349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Xamoterol, a new selective beta-1-adrenoceptor partial agonist, in the treatment of postural hypotension.
    Mehlsen J; Trap-Jensen J
    Acta Med Scand; 1986; 219(2):173-7. PubMed ID: 2870611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exercise capacity, arrhythmias, humoral and chemical parameters during long-term therapy with xamoterol.
    Erlemeier HH; Kupper W; Bleifeld W
    Int J Cardiol; 1990 Aug; 28(2):197-208. PubMed ID: 1697569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Xamoterol in severe congestive heart failure: long-term oral treatment, a double-blind randomised study.
    Tangø M; Lyngborg K; Mehlsen J; Svendsen TL; Trap-Jensen J
    Int J Cardiol; 1992 Jan; 34(1):63-8. PubMed ID: 1347763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical experience of therapy with xamoterol in patients with severe systolic and diastolic dysfunction.
    Pouleur H; Hanet C; Rousseau MF
    Eur Heart J; 1990 Apr; 11 Suppl A():33-8. PubMed ID: 1971587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haemodynamics in postural hypotension--effects of the beta-adrenoceptor partial agonist xamoterol, and pindolol.
    Mehlsen J; Trap-Jensen J
    Eur Heart J; 1990 Apr; 11 Suppl A():56-8. PubMed ID: 1971593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ischaemic left ventricular failure: evidence of sustained benefit after 18 months' treatment with xamoterol.
    Vigholt-Sørensen E; Faergeman O
    Br Heart J; 1990 Sep; 64(3):186-9. PubMed ID: 1976339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The value of xamoterol in moderate ischemic cardiac insufficiency].
    Rousseau MF; Cheron P; Vincent MF; Pouleur H; Lavenne F
    Ann Cardiol Angeiol (Paris); 1984; 33(4):215-8. PubMed ID: 6147115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute and chronic hemodynamic effects of xamoterol in mild to moderate congestive heart failure.
    Virk SJ; Qiang FX; Anfilogoff NH; Murray RG; Littler WA; Davies MK
    Am J Cardiol; 1991 May; 67(12):48C-52C; discussion 52C-54C. PubMed ID: 1673587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Xamoterol in hypertrophic cardiomyopathy: effects on diastolic function and heart rate.
    Gilligan DM; Stewart R; Chan WL; Oakley CM
    Int J Cardiol; 1992 Jun; 35(3):377-86. PubMed ID: 1351887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral xamoterol in patients with sinoatrial disease.
    Tseu FL; Morley CA; Mackintosh AF
    Br Heart J; 1986 Nov; 56(5):469-72. PubMed ID: 2878676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.